Mechanism of action
VERQUVO® (vericiguat) employs a novel MOA for the treatment of HF, resulting in smooth muscle relaxation and vasodilation1
VERQUVO augments cGMP levels by addressing impaired NO-sGC-cGMP pathway, which is important in the pathophysiology of HF.
HF is associated with low NO bioavailability, decreased sGC activity, and reduced cGMP synthesis leading to vascular dysfunction and myocardial dysfunction
VERQUVO directly stimulates sGC, independently of and synergistically with NO, to produce more cGMP leading to smooth muscle relaxation and vasodilation which may improve cardiac function.
cGMP = cyclic guanosine monophosphate; HF = heart failure; MOA = mechanism of action; MOD= mechanism of disease; NO = nitric oxide; sGC = soluble guanylate cyclase
1. Armstrong PW, Pieske B, Anstrom KJ, et al. Vericiguat in patients with heart failure and reduced ejection fraction. N Engl J Med. 2020;382(20):1883-1893.